Resistance to targeted therapies: delving into FLT3 and IDH

Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impac...

Descripción completa

Detalles Bibliográficos
Autores principales: Desikan, Sai Prasad, Daver, Naval, DiNardo, Courtney, Kadia, Tapan, Konopleva, Marina, Ravandi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184476/
https://www.ncbi.nlm.nih.gov/pubmed/35680852
http://dx.doi.org/10.1038/s41408-022-00687-5
_version_ 1784724527034400768
author Desikan, Sai Prasad
Daver, Naval
DiNardo, Courtney
Kadia, Tapan
Konopleva, Marina
Ravandi, Farhad
author_facet Desikan, Sai Prasad
Daver, Naval
DiNardo, Courtney
Kadia, Tapan
Konopleva, Marina
Ravandi, Farhad
author_sort Desikan, Sai Prasad
collection PubMed
description Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.
format Online
Article
Text
id pubmed-9184476
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91844762022-06-11 Resistance to targeted therapies: delving into FLT3 and IDH Desikan, Sai Prasad Daver, Naval DiNardo, Courtney Kadia, Tapan Konopleva, Marina Ravandi, Farhad Blood Cancer J Review Article Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance. Nature Publishing Group UK 2022-06-09 /pmc/articles/PMC9184476/ /pubmed/35680852 http://dx.doi.org/10.1038/s41408-022-00687-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Desikan, Sai Prasad
Daver, Naval
DiNardo, Courtney
Kadia, Tapan
Konopleva, Marina
Ravandi, Farhad
Resistance to targeted therapies: delving into FLT3 and IDH
title Resistance to targeted therapies: delving into FLT3 and IDH
title_full Resistance to targeted therapies: delving into FLT3 and IDH
title_fullStr Resistance to targeted therapies: delving into FLT3 and IDH
title_full_unstemmed Resistance to targeted therapies: delving into FLT3 and IDH
title_short Resistance to targeted therapies: delving into FLT3 and IDH
title_sort resistance to targeted therapies: delving into flt3 and idh
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184476/
https://www.ncbi.nlm.nih.gov/pubmed/35680852
http://dx.doi.org/10.1038/s41408-022-00687-5
work_keys_str_mv AT desikansaiprasad resistancetotargetedtherapiesdelvingintoflt3andidh
AT davernaval resistancetotargetedtherapiesdelvingintoflt3andidh
AT dinardocourtney resistancetotargetedtherapiesdelvingintoflt3andidh
AT kadiatapan resistancetotargetedtherapiesdelvingintoflt3andidh
AT konoplevamarina resistancetotargetedtherapiesdelvingintoflt3andidh
AT ravandifarhad resistancetotargetedtherapiesdelvingintoflt3andidh

Ejemplares similares